Firy Inc. vs Cassava Sciences Inc — how do they compare? Firy Inc. trades at $8.37 (market cap $125.48M), while Cassava Sciences Inc trades at $1.08 (market cap $53.14M). The key difference: Firy Inc. is far larger — about 2.4× Cassava Sciences Inc's market cap, and Firy Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FIRY | FLNA | |
|---|---|---|
Market Cap | $125.48M | $53.14M |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $4.64 |
52-Week Low | $2.28 | $1.09 |
Enterprise Value | $69.16M | -$33.43M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →